EMERYVILLE, Calif., April 26 /PRNewswire-FirstCall/ -- Dr. Isaac Cohen, President and CEO of Bionovo, Inc. , a drug development company focusing on the discovery of novel pharmaceutical agents for cancer and women’s health, was interviewed by television stations across the country yesterday. These interviews were part of the Company’s extensive program to help educate the public on menopause-related topics such as ancient Asian remedies, modern breakthrough treatments, issues surrounding hormone replacement therapy (HRT), and how to help relieve the often harsh symptoms.
Among the television stations featuring Dr. Cohen were WGHP-FOX in Greensboro, NC, WTVF-CBS in Nashville, and WGEM-CBS in Quincy, IL.
In his interviews, Dr. Cohen discussed how for 75% of women, menopause often brings with it such debilitating symptoms as mild to severe hot flashes, mood instability, weight gain, brittle bones, increased risk of heart disease, and sexual problems as well as which treatment options are both safe and effective.
As part of the initiative, Dr. Cohen’s The New Menopause Book (Avery/Penguin), which he co-edited with several other renowned menopause experts, also helps clarify most of the peri-menopause and menopause issues women face. For example, the book addresses the pros and cons of HRT, ways to prevent osteoporosis, and alternative treatments for relief of symptoms.
Those interested in receiving a CD of the aired interviews may submit their request to dmcintosh@investorrelationsgroup.com.
Bionovo, Inc.
Bionovo is a drug development company focusing on the discovery of novel pharmaceutical agents for cancer and women’s health. The company is working simultaneously on two distinct discovery approaches, one focusing on pro- apoptotic agents for cancer and a second, in the area of selective estrogen receptor modulators (SERMS) to treat severe menopausal symptoms. The company’s lead candidate drug, MF101 is in Phase 2 clinical testing and a second drug, BZL101, designed to treat advanced breast cancer is ready to enter Phase 2. The company is developing its products in close collaboration with leading U.S. academic research centers including the University of California, San Francisco; University of Colorado Health Sciences Center; University of California, Berkeley; and the University of Texas, Southwestern. For further information please visit: www.bionovo.com.
Forward-Looking Statements
This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as “believes,” “expects,” or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at www.sec.gov. Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.
Bionovo, Inc.
CONTACT: Jim Stapleton, Chief Financial Officer of BioNovo, Inc.,+1-510-601-2000, or jim@bionovo.com; or Antima “Taz” Sadhukhan, or Media:Janet Vasquez, both of Investor Relations Group, +1-212-825-3210, forBioNovo, Inc.
Web site: http://www.bionovo.com/
